pemvidutide stock shows promise in obesity, NASH markets By Investing.com
Altimmune, Inc. (NASDAQ:), a biotechnology company with a market capitalization of $483 million focused on developing treatments for obesity and liver diseases, has been garnering attention from analysts and investors alike due to its promising drug candidate, pemvidutide. According to InvestingPro data, analyst price targets range from $12 to $28, suggesting significant potential upside from current levels. This comprehensive analysis delves into the company’s potential, challenges, and market positioning as it progresses through clinical trials and aims to make a significant impact in the obesity and non-alcoholic steatohepatitis (NASH) treatment landscapes.
Pemvidutide: A Promising GLP/Glucagon Agonist
Pemvidutide, Altimmune’s lead…
